Skip to Content
Merck
  • Transporter-mediated uptake of UDP-glucuronic acid by human liver microsomes: assay conditions, kinetics, and inhibition.

Transporter-mediated uptake of UDP-glucuronic acid by human liver microsomes: assay conditions, kinetics, and inhibition.

Drug metabolism and disposition: the biological fate of chemicals (2014-11-09)
Andrew Rowland, Peter I Mackenzie, John O Miners
ABSTRACT

This study characterized the kinetics, variability, and factors that affect UDP-glucuronic acid (UDP-GlcUA) uptake by human liver microsomes (HLM). Biphasic kinetics were observed for UDP-GlcUA uptake by HLM. Uptake affinities (assessed as Kd) of the high- and low-affinity components differed by more than an order of magnitude (13 ± 6 vs. 374 ± 175 µM), but were comparable in terms of the maximal rate of uptake, with mean Vmax values differing less than 2.3-fold (56 ± 26 vs. 131 ± 35 pmol/min per mg). Variability in total intrinsic transporter activity (Uint) for microsomal UDP-GlcUA uptake across 12 livers was less than 4-fold. Experiments performed to optimize the conditions for microsomal UDP-GlcUA uptake demonstrated that both components were trans-stimulated by preloading (luminal addition) with an alternate UDP-sugar, and essentially abolished by the thiol-alkylating agent N-ethylmaleimide. Furthermore, interaction studies undertaken with a panel of drugs, alternate UDP-sugars, and glucuronide conjugates, at low (2.5 μM) and high (1000 μM) UDP-GlcUA concentrations, demonstrated that both components were inhibited to varying extents. Notably, the nucleoside analogs zidovudine, stavudine, lamivudine, and acyclovir inhibited both the high- and low- affinity components of microsomal UDP-GlcUA uptake by >45% at an inhibitor concentration of 100 μM. Taken together, these data demonstrate that human liver microsomal UDP-GlcUA uptake involves multiple protein-mediated components, and raises the possibility of impaired in vivo glucuronidation activity resulting from inhibition of UDP-GlcUA uptake into the endoplasmic reticulum membrane by drugs and other compounds.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Formic acid, ≥95%, FCC, FG
Sigma-Aldrich
Acycloguanosine, ≥99% (HPLC), powder
Sigma-Aldrich
p-Acetamidophenyl β-D-glucuronide sodium salt, >98% (TLC)
Sigma-Aldrich
4-Methylumbelliferone, ≥98%
Sigma-Aldrich
Uridine 5′-diphospho-N-acetylglucosamine sodium salt, ≥98%
Sigma-Aldrich
Uridine 5′-diphosphoglucose disodium salt, ≥98.0% (HPLC)
Aciclovir, European Pharmacopoeia (EP) Reference Standard
Sigma-Aldrich
Acetonitrile solution, contains 0.1 % (v/v) trifluoroacetic acid, suitable for HPLC
Sigma-Aldrich
Lamivudine, ≥98% (HPLC), powder
Sigma-Aldrich
Formic acid, puriss., meets analytical specifications of DAC, FCC, 98.0-100%
Sigma-Aldrich
Formic acid, ACS reagent, ≥96%
Sigma-Aldrich
Formic acid, puriss. p.a., ACS reagent, reag. Ph. Eur., ≥98%
Supelco
Zidovudine, Pharmaceutical Secondary Standard; Certified Reference Material
Zidovudine, European Pharmacopoeia (EP) Reference Standard
Supelco
Lamivudine, Pharmaceutical Secondary Standard; Certified Reference Material
Lamivudine, European Pharmacopoeia (EP) Reference Standard
Lamivudine for system suitability 1, European Pharmacopoeia (EP) Reference Standard
Lamivudine for system suitability 2, European Pharmacopoeia (EP) Reference Standard
Supelco
Acyclovir, Pharmaceutical Secondary Standard; Certified Reference Material
Supelco
Residual Solvent - Acetonitrile, Pharmaceutical Secondary Standard; Certified Reference Material
Hymecromone, European Pharmacopoeia (EP) Reference Standard
Sigma-Aldrich
Formic acid, reagent grade, ≥95%
Sigma-Aldrich
Formic acid, ACS reagent, ≥88%
Sigma-Aldrich
Ultrapure Acetonitrile